NCT01133873TerminatedPhase 4
A Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Study of Sequential Ascending Dose Levels to Assess the Safety, Tolerability and Electrocardiographic Effects of Propoxyphene Napsylate Capsules (and Its Metabolite Norpropoxyphene) When Administered Orally to Healthy Adult Subjects
Xanodyne Pharmaceuticals1 site in 1 country48 target enrollmentStarted: June 2010Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Terminated
- Sponsor
- Enrollment
- 48
- Locations
- 1
- Primary Endpoint
- Determine the safety and tolerability of propoxyphene napsylate as determined by evaluation of adverse events, change from baseline of ventricular repolarization, lab results, and mental status
Study Overview
Brief Summary
The purpose of this study is to determine the daily maximum tolerated dose of propoxyphene napsylate in healthy subjects.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 49 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Body mass index ≥ 18 and ≤ 30 (kg/m2)
- •Medically healthy with normal screening results, or in the case of results that are abnormal; the abnormal results are clinically insignificant (eg, medical history, physical examination, neurological assessment, vital signs, oxygen saturation, laboratory profiles)
- •12-lead ECGs (calculations by the electrocardiograph) which have no clinically significant findings
- •Vital signs which are within normal range
- •No tobacco/nicotine-containing product use for a minimum of 6 months
- •If female, must be able to adhere to acceptable methods of contraception or be postmenopausal or surgically sterile
Exclusion Criteria
- •History or presence of significant cardiovascular, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, or neurological disease
- •History or presence of any degree of chronic obstructive pulmonary disease
- •History of suicidal ideations or depression requiring professional intervention including counseling or antidepressant medication
- •Any history of drug or alcohol abuse
- •Positive drug (urine)/alcohol (breath) testing at screening or check-in
- •Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV)
- •History of hypersensitivity or allergy to propoxyphene or any opioid compound, naloxone, naltrexone, palonosetron (Aloxi®), glycerin, senna, or bisacodyl (Dulcolax®)
- •Use of any prescription medication (with the exception of hormonal contraceptives for females) within 2 weeks of enrollment
- •Use of any over-the-counter medication, including herbal products, within 1 week of enrollment
- •Use of any drugs known to significantly inhibit or induce liver enzymes involved in drug metabolism [CYP P450]) within 30 days of enrollment
- •Blood donation or significant blood loss within 30 days of enrollment
- •Plasma donation within 7 days of enrollment
- •Participation in another clinical trial within 30 days of enrollment
- •Females who are pregnant or lactating
- •Any other condition or prior therapy, which, in the opinion of the PI, would make the subject unsuitable for this study
Arms & Interventions
1
Experimental
Intervention: Propoxyphene napsylate (XP20C) (Drug)
2
Placebo Comparator
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Determine the safety and tolerability of propoxyphene napsylate as determined by evaluation of adverse events, change from baseline of ventricular repolarization, lab results, and mental status
Time Frame: Day 13
Secondary Outcomes
- Establish the relationship between serum concentrations of propoxyphene and norpropoxyphene on cardiac conduction and pharmacokinetic linearity of sequentially increased dose levels of propoxyphene napsylate.(Days -1, 1, 4, 11)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Evaluation of the Safety and Potential Therapeutic Effects of Cordstem-ST in Patients With Cerebral InfarctionCerebral InfarctionNCT02378974CHABiotech CO., Ltd18
Completed
Phase 1
Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy VolunteersHealthyNCT02572349Cyclerion Therapeutics24
Terminated
Phase 1
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788HealthyNCT02255968Enanta Pharmaceuticals, Inc16
Completed
Phase 3
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)Irritable Bowel SyndromeNCT01553747Furiex Pharmaceuticals, Inc1,146
Completed
Phase 3
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)Irritable Bowel SyndromeNCT01553591Furiex Pharmaceuticals, Inc1,282